REGN9933
- Generic Name
- REGN9933
Regeneron's Factor XI Antibodies Show Promise in Phase 2, Advancing to Phase 3
• Regeneron's REGN7508 demonstrated superior efficacy to enoxaparin in preventing venous thromboembolism (VTE) after knee surgery, with a 7% VTE event rate compared to 21%.
• REGN9933 showed non-inferiority to enoxaparin in VTE prevention post-knee surgery, offering a potential option for patients at high bleeding risk.
• Both REGN7508 and REGN9933 exhibited robust antithrombotic effects with no clinically relevant bleeding observed in Phase 2 trials.
• Regeneron plans to initiate Phase 3 trials for REGN7508 and REGN9933 in 2025, marking a significant step in developing safer anticoagulation therapies.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath